Joong Myung Cho – Chairman & CEO, CrystalGenomics, South Korea
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery…
Ahn-Gook Pharmaceutical Co. Ltd has developed and supplied outstanding medicines for the last 45 years, dedicated to developing “advanced pharmaceutical products for health and happiness of the mankind.” As a result of this sustainable effort and growth Ahn-Gook has achieved KOSDAQ enlistment and transparent management as a recognized pharmaceutical developer. Ahn-Gook has set a new vision to realize “new world-class medicine and global marketing by 2020.” In the 21st century, only companies with core technology and key manpower survive. Therefore, Ahn-Gook is accumulating core technology to develop new world-class medicine and fostering key manpower for developing and marketing our new medicines.
Contact details
993-75 Daerim-2-dong Yeongdeungpo-gu, Seoul
TEL +82 2 3289 4200
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery…
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO),…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea,…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug…